-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicara Therapeutics Announces Publication Of An Abstract With Updated Interim Data From Phase 1/1b Trial Of Ficerafusp alfa In 1L R/M HNSCC At The 2025 ASCO Annual Meeting; Updated Phase 1/1b Data For Ficerafusp Alfa In Head And Neck Cancer Shows Mixed Results, With Median Survival Still Unreached And Limited Clarity On Long-Term Efficacy

Benzinga·05/22/2025 21:12:12
Listen to the news

Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset, including overall survival (OS) and duration of response (DOR) data, following an oral presentation of the data at the ASCO Annual Meeting. Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by breaking barriers within the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).